T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis
2013 (English)In: Immunology, ISSN 0019-2805, E-ISSN 1365-2567, Vol. 140, no 2, 211-219 p.Article in journal (Refereed) Published
Autologous haematopoietic stem cell transplantation (HSCT) for relapsing-remitting multiple sclerosis is a potentially curative treatment, which can give rise to long-term disease remission. However, the mode of action is not yet fully understood. The aim of the study was to evaluate similarities and differences of the CD4(+) T-cell populations between HSCT-treated patients (n = 12) and healthy controls (n = 9). Phenotyping of memory T cells, regulatory T (Treg) cells and T helper type 1 (Th1) and type 17 (Th17) cells was performed. Further, T-cell reactivity to a tentative antigen, myelin oligodendrocyte glycoprotein, was investigated in these patient populations. Patients treated with natalizumab (n = 15) were included as a comparative group. White blood cells were analysed with flow cytometry and T-cell culture supernatants were analysed with magnetic bead panel immunoassays. HSCT-treated patients had similar levels of Treg cells and of Th1 and Th17 cells as healthy subjects, whereas natalizumab-treated patients had lower frequencies of Treg cells, and higher frequencies of Th1 and Th17 cells. Cells from HSCT-treated patients cultured with overlapping peptides from myelin oligodendrocyte glycoprotein produced more transforming growth factor-beta(1) than natalizumab-treated patients, which suggests a suppressive response. Conversely, T cells from natalizumab-treated patients cultured with those peptides produced more interleukin-17 (IL-17), IL-1 and IL-10, indicating a Th17 response. In conclusion, we demonstrate circumstantial evidence for the removal of autoreactive T-cell clones as well as development of tolerance after HSCT. These results parallel the long-term disease remission seen after HSCT.
Place, publisher, year, edition, pages
2013. Vol. 140, no 2, 211-219 p.
haematopoietic stem cell transplantation, multiple sclerosis, natalizumab, neuroimmunology
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-211463DOI: 10.1111/imm.12129ISI: 000324303200007OAI: oai:DiVA.org:uu-211463DiVA: diva2:667154